Skip to main content
Log in

Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival

  • Original Article
  • Published:
Japanese Journal of Radiology Aims and scope Submit manuscript

Abstract

Purpose

To determine the treatment outcome and prognostic factors for survival in patients with hepatocellular carcinoma (HCC) and macrovascular tumor thrombosis (MTT).

Methods

Between January 2010 and December 2018, 66 patients diagnosed with HCC and MTT, who received specific treatment were included. Various clinical and imaging data, treatment methods, outcomes, prognostic factors, and overall survival were evaluated. Outcomes were compared with those of 24 patients treated with supportive care.

Results

Most patients with HCC and MTT showed disease progression (80.3%) and a low 5-year survival rate. The median survival time after treatment was 13 months (vs. supportive care group 3 months, p < 0.001). Main branch MTT (p = 0.036), extent of tumor thrombus > 1 segment (p = 0.039), presence of ascites (p = 0.009) and among treatment methods, systemic therapy alone (p = 0.007), and supportive care (p < 0.001) compared with combined local with systemic therapies were prognostic factors for poor survival.

Conclusions

Although most patients with HCC and MTT showed disease progression, median survival time was significantly longer than that with supportive care. Main branch and > 1 segment involvement of MTT and presence of ascites were significant prognostic factors for poor survival. Combined local and systemic therapy over systemic therapy alone are recommended for patients with these advanced stage HCCs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    PubMed  CAS  Google Scholar 

  2. Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016. World J Gastroenterol. 2016;22:7289–300.

    PubMed  PubMed Central  Google Scholar 

  3. Costentin CE, Ferrone CR, Arellano RS, Ganguli S, Hong TS, Zhu AX. Hepatocellular carcinoma with macrovascular invasion: defining the optimal treatment strategy. Liver Cancer. 2017;6:360–74.

    PubMed  PubMed Central  CAS  Google Scholar 

  4. Liu PH, Huo TI, Miksad RA. Hepatocellular carcinoma with portal vein tumor involvement: best management strategies. Semin Liver Dis. 2018;38:242–51.

    PubMed  CAS  Google Scholar 

  5. Jiang JF, Lao YC, Yuan BH, Yin J, Liu X, Chen L, et al. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget. 2017;8:33911–21.

    PubMed  PubMed Central  Google Scholar 

  6. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, MD). 2018;67:358–80.

    Google Scholar 

  7. Aghemo A. Update on HCC management and review of the new EASL guidelines. Gastroenterol Hepatol. 2018;14:384–6.

    Google Scholar 

  8. Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol. 2015;50:445–54.

    PubMed  CAS  Google Scholar 

  9. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.

    PubMed  CAS  Google Scholar 

  10. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–70.

    PubMed  PubMed Central  Google Scholar 

  11. Kudo M, Kitano M, Sakurai T, Nishida N. General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the liver cancer study group of Japan. Dig Dis (Basel, Switzerland). 2015;33:765–70.

    Google Scholar 

  12. Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146(1691–700):e3.

    Google Scholar 

  13. Korean Liver Cancer Study Group (KLCSG) and National Cancer Center (NCC). 2014 KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma. Gut Liver. 2015;9:267–317.

  14. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.

    PubMed  CAS  Google Scholar 

  15. Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, et al. Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2016;46:372–90.

    PubMed  Google Scholar 

  16. Lo YC, Hsu FC, Hung SK, Tseng KC, Hsieh YH, Lee MS, et al. Prognosticators of hepatocellular carcinoma with intrahepatic vascular invasion. Ci ji yi xue za zhi = Tzu-chi Med J. 2019;31:40–6.

    Google Scholar 

  17. Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011;18:413–20.

    PubMed  Google Scholar 

  18. Kim JH, Shim JH, Yoon HK, Ko HK, Kim JW, Gwon DI. Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein. Liver Int. 2018;38:1646–54.

    PubMed  Google Scholar 

  19. Sinn DH, Cho JY, Gwak GY, Paik YH, Choi MS, Lee JH, et al. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS ONE. 2015;10:e0124434.

    PubMed  PubMed Central  Google Scholar 

  20. Yoneda N, Matsui O, Kobayashi S, Kitao A, Kozaka K, Inoue D, et al. Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma. Jpn J Radiol. 2019;37:191–208.

    PubMed  CAS  Google Scholar 

  21. Jang TY, Huang CI, Yeh ML, Lin ZY, Chen SC, Chuang WL. The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis. Medicine. 2019;98:e15066.

    PubMed  PubMed Central  Google Scholar 

  22. Silva JP, Berger NG, Tsai S, Christians KK, Clarke CN, Mogal H, et al. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. HPB (Oxford). 2017;19:659–66.

    Google Scholar 

  23. Huo L, Wei W, Yan Z, Lei Z, Xie Y, Gong R, et al. Short-term and long-term outcomes of liver resection for HCC patients with portal vein tumor thrombus. Cell Biosci. 2019;9:23.

    PubMed  PubMed Central  Google Scholar 

  24. Ajit Y, Sudarsan H, Saumya G, Abhishek A, Navneet R, Piyush R, et al. Transarterial chemoembolization in unresectable hepatocellular carcinoma with portal vein thrombosis: a perspective on survival. Oman Med J. 2014;29:430–6.

    PubMed  PubMed Central  Google Scholar 

  25. Abdelmaksoud AH, Mandooh S, Nabeel MM, Elbaz TM, Shousha HI, Monier A, et al. Portal vein thrombosis in unresectable Hcc cases: a single center study of prognostic factors and management in 140 patients. Asian Pac J Cancer Prev. 2017;18:183–8.

    PubMed  PubMed Central  Google Scholar 

  26. Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Michitaka K, et al. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: an analysis using time-dependent receiver operating characteristic. J Gastroenterol Hepatol. 2019;34:1066–73.

    PubMed  CAS  Google Scholar 

  27. Mohammed MAA, Khalaf MH, Liang T, Wang DS, Lungren MP, Rosenberg J, et al. Albumin-bilirubin score: an accurate predictor of hepatic decompensation in high-risk patients undergoing transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol JVIR. 2018;29(1527–34):e1.

    Google Scholar 

  28. Liu C, Xiao GQ, Yan LN, Li B, Jiang L, Wen TF, et al. Value of alpha-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J Gastroenterol. 2013;19:1811–9.

    PubMed  PubMed Central  CAS  Google Scholar 

  29. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65:938–43.

    PubMed  Google Scholar 

  30. Zhang ZM, Lai EC, Zhang C, Yu HW, Liu Z, Wan BJ, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg. 2015;20:8–16.

    PubMed  Google Scholar 

  31. Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol. 2013;13:60.

    PubMed  PubMed Central  Google Scholar 

  32. Le Y, Shen JX, Zhang YF, He MK, Kan A, Chen HL, et al. Transarterial chemoembolization related to good survival for selected patients with advanced hepatocellular carcinoma. J Cancer. 2019;10:665–71.

    PubMed  PubMed Central  Google Scholar 

  33. Abdella H, Shaker MK, Montasser IF, Sobhi M, Aly H, Sayed A, et al. Outcome of transarterial chemoembolization in Egyptian patients with hepatocellular carcinoma and branch portal vein thrombosis. Indian J Gastroenterol. 2018;37:127–32.

    PubMed  CAS  Google Scholar 

  34. Jeong Y, Shin MH, Yoon SM, Song GW, Kim KH, Ahn CS, et al. Liver transplantation after transarterial chemoembolization and radiotherapy for hepatocellular carcinoma with vascular invasion. J Gastrointest Surg. 2017;21:275–83.

    PubMed  Google Scholar 

  35. Kim GA, Shim JH, Yoon SM, Jung J, Kim JH, Ryu MH, et al. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. J Vasc Interv Radiol JVIR. 2015;26:320 e6–9 e6.

    Google Scholar 

  36. Li MF, Leung HW, Chan AL, Wang SY. Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion. Ther Clin Risk Manag. 2018;14:1157–68.

    PubMed  PubMed Central  CAS  Google Scholar 

  37. Shen L, Xi M, Zhao L, Zhang X, Wang X, Huang Z, et al. Combination therapy after TACE for hepatocellular carcinoma with macroscopic vascular invasion: stereotactic body radiotherapy versus sorafenib. Cancers. 2018;10:516.

    PubMed Central  Google Scholar 

  38. Hu H, Duan Z, Long X, Hertzanu Y, Shi H, Liu S, et al. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. PLoS ONE. 2014;9:e96620.

    PubMed  PubMed Central  Google Scholar 

  39. Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology. 2013;269:603–11.

    PubMed  Google Scholar 

  40. Somma F, Stoia V, Serra N, D'Angelo R, Gatta G, Fiore F. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: the impact of portal vein thrombosis on survival. PLoS ONE. 2019;14:e0216935.

    PubMed  PubMed Central  CAS  Google Scholar 

  41. Kodama K, Kawaoka T, Aikata H, Uchikawa S, Inagaki Y, Hatooka M, et al. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. J Gastroenterol Hepatol. 2018;33:1780–6.

    PubMed  CAS  Google Scholar 

  42. Jia Z, Jiang G, Tian F, Zhu C, Qin X. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Saudi J Gastroenterol. 2016;22:353–9.

    PubMed  PubMed Central  Google Scholar 

  43. Kim PH, Choi SH, Kim JH, Park SH. Comparison of radioembolization and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis of safety and efficacy. Korean J Radiol. 2019;20:385–98.

    PubMed  PubMed Central  Google Scholar 

  44. Finn RS, Zhu AX, Farah W, Almasri J, Zaiem F, Prokop LJ, et al. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and meta-analysis. Hepatology (Baltimore, MD). 2018;67:422–35.

    CAS  Google Scholar 

  45. Han K, Kim JH, Ko GY, Gwon DI, Sung KB. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: a comprehensive review. World J Gastroenterol. 2016;22:407–16.

    PubMed  PubMed Central  CAS  Google Scholar 

  46. Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol. 2018;4:661–9.

    PubMed  PubMed Central  Google Scholar 

Download references

Funding

No funding was received for this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Myung-Won You.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical statement

This study was approved by our institutional review board and informed consent was waived, because this is a retrospective study using pre-existing data. We declare that all human studies have been performed in accordance with the ethical standards laid down in the 1964 Helsinki declaration and its later amendments.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 21 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, N., You, MW. Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival. Jpn J Radiol 37, 781–792 (2019). https://doi.org/10.1007/s11604-019-00868-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11604-019-00868-6

Keywords

Navigation